Global incidence in hospital-associated infections resistant to antibiotics: An analysis of point prevalence surveys from 99 countries

PLoS Med. 2023 Jun 13;20(6):e1004178. doi: 10.1371/journal.pmed.1004178. eCollection 2023 Jun.

Abstract

Background: Hospital-associated infections (HAIs) are an important cause of morbidity and mortality around the world. Many HAIs are caused by drug-resistant bacterial pathogens, but there are major gaps in our understanding of the number of hospital-associated drug-resistant infections (HARIs) worldwide. As such, we estimated trends in prevalence of HARIs caused by high priority pathogens (Escherichia coli, Acinetobacter spp., Klebsiella spp., Staphylococcus aureus, Enterobacter spp., and Pseudomonas spp.) in 195 countries.

Methods and findings: Resistance prevalence estimates were extracted from 474-point prevalence surveys (PPS) from 99 countries published between 2010 and 2020 coupled with country-level estimates of hospitalization rates and length of stay. Prevalence estimates were transformed in yearly incidence of HARIs per year by country and income group. We estimate the global number of HARIs per year to be 136 million (95% credible interval (CI) 26 to 246 million) per year, with the highest burden in China (52 million, 95% CI 10 to 95 million), Pakistan (10 million, 95% CI 2 to 18 million), and India (9 million, 95% CI 3 to 15 million). Among income groups, middle-income countries bore the highest burden of HARIs per year (119 million, 95% CI 23 to 215 million). Our analysis was constrained by the limited number of PPS for HARIs, lack of community-associated data on antibiotic-resistant infections, and our population level analysis.

Conclusions: In this study, we observe, in the absence of systematic surveillance systems for HARIs, a baseline overview of their rates. Our yearly estimates highlight the global threat of HARIs and may help define strategies to tackle resistance in hospital settings.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Cross Infection* / drug therapy
  • Cross Infection* / epidemiology
  • Escherichia coli
  • Hospitals
  • Humans
  • Incidence
  • Prevalence

Substances

  • Anti-Bacterial Agents

Grants and funding

RB and RL received support from NSF grant CCF-1918628 to the Center for Disease Dynamics, Economics & Policy (https://beta.nsf.gov/funding), the US Centers for Disease Control and Prevention IPA (21IPA2113462) (https://www.cdc.gov/funding/index.html), and the BIll and Melinda Gates Foundation grant OPP1190803. TPVB was supported by the Branco Weiss Foundation and the Eccellenza Program from the Swiss National Science Foundation (181248) (https://brancoweissfellowship.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.